COVID Clinical Trial
Official title:
Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study
Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by
SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with pneumonia, but
can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system.
In previous reports of SARS and MERS-CoV infections, acute kidney injury was described in 5
to 15% of patients and was associated with a high mortality rate (60-90%). Recent reports
showed renal abnormalities in COVID-9 infected patients. A recent Chinese study also reported
that acute kidney injury was an independent risk factor for mortality. However, the exact
mechanism of kidney involvement remains unclear: sepsis-related cytokine storm or direct
cellular injury from the virus. Also, kidney involvement has not yet been well characterized:
heavy albuminuria, hematuria or interstitial nephropathy alone.
A recent study identified viral RNA in kidney tissue and another study succeeded isolating
SARS-CoV-2 from the urine sample of an infected patient. These data suggest that the kidney
might be a target of this novel coronarivus.
The sponsor suggests characterizing kidney involvement in SARS-CoV-2 infection.
Study objectives are:
- To give an accurate characterization of kidney involvement in COVID-19
- To investigate the physiopathologic mechanism of kidney involvement in SARS-CoV-2
infection
- To identify risk factors for kidney involvement in in SARS-CoV-2 infection
- To evaluate the impact of kidney involvement in in SARS-CoV-2 infection
- To assess the long-term health effect of kidney injury on survivors of in SARS-CoV-2
infection
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
| Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
| Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
| Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
| Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
| Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
| Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
| Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
| Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |